Abdul-Ghani A S, Attwell P J, Singh Kent N, Bradford H F, Croucher M J, Jane D E
Department of Biology and Biochemistry, Birzeit University, West-Bank, Israel.
Brain Res. 1997 May 2;755(2):202-12. doi: 10.1016/s0006-8993(97)00098-x.
The protective effect of amygdaloid (focally administered) doses of the presynaptic metabotropic glutamate receptor agonist, L-2-amino-4-phosphonobutyrate (L-AP4) was tested on the development of electrical kindling and in fully kindled animals. L-AP4 inhibited epileptogenesis at 10 nmol in 0.5 microl buffer, by preventing the increase in both seizure score and afterdischarge duration. The effects were reversible after withdrawal of the drug, with all treated animals subsequently progressing to the fully kindled state at the same rate as control animals. The same concentration of the drug was also effective when injected into fully kindled animals. It significantly decreased the mean seizure score by 88% (P < 0.005) and increased the mean generalized seizure threshold (GST) by 85% (P < 0.005). The increase in GST was accompanied by a significant delay before the onset of generalized seizure and by a 37% reduction in generalized seizure duration. MPPG ((RS)-alpha-methyl-4-phosphonophenyl glycine) a selective antagonist of L-AP4 at glutamate pre-synaptic receptors inhibited the depressant effect of L-AP4 in a dose-dependent manner. MPPG (10 nmol) inhibited the antiseizure activity of L-AP4, whilst MPPG (40 nmol) reduced both the anti-epileptogenic and antiseizure activities of L-AP4. MPPG (40 nmol) by itself had no effect on generalized seizure activity, and it had no detectable influence on the normal rate of kindled epileptogenesis. During in vitro studies using a microsuperfusion method, L-AP4 inhibited depolarization-induced release of [3H]D-aspartate from rat cortical synaptosomes (IC50 125.1 microM) and decreased the depolarization-evoked uptake of 45Ca2+ in a dose-dependent manner. Both actions of L-AP4 were reduced by the selective antagonist MPPG. When applied alone MPPG (200 microM) had no detectable action on veratridine-evoked 45Ca2+ uptake by the synaptosomes. These results suggest the mechanisms by which presynaptically active glutamate receptor agonists block the development of the chronically epileptic state induced by electrical kindling, and indicate that their anticonvulsive activity is due to inhibition of presynaptic glutamate and/or aspartate release following blockade of presynaptic Ca2+ entry.
研究了杏仁核局部注射突触前代谢型谷氨酸受体激动剂L-2-氨基-4-膦酸丁酸(L-AP4)对电点燃发展过程及完全点燃动物的保护作用。L-AP4在0.5微升缓冲液中10纳摩尔时可抑制癫痫发生,通过阻止癫痫发作评分和放电后持续时间的增加来实现。停药后这些作用是可逆的,所有接受治疗的动物随后都以与对照动物相同的速度发展到完全点燃状态。将相同浓度的该药物注射到完全点燃的动物中也有效。它使平均癫痫发作评分显著降低88%(P<0.005),并使平均全身性癫痫发作阈值(GST)提高85%(P<0.005)。GST的升高伴随着全身性癫痫发作开始前的显著延迟以及全身性癫痫发作持续时间减少37%。MPPG((RS)-α-甲基-4-膦酰基苯基甘氨酸)是L-AP4在谷氨酸突触前受体上的选择性拮抗剂,以剂量依赖性方式抑制L-AP4的抑制作用。MPPG(10纳摩尔)抑制L-AP4的抗癫痫活性,而MPPG(40纳摩尔)则降低L-AP4的抗癫痫发生和抗癫痫活性。MPPG(40纳摩尔)自身对全身性癫痫发作活动无影响,且对点燃癫痫发生的正常速率无可检测的影响。在使用微灌注方法的体外研究中,L-AP4抑制大鼠皮质突触体中去极化诱导的[3H]D-天冬氨酸释放(IC50为125.1微摩尔),并以剂量依赖性方式降低去极化诱发的45Ca2+摄取。L-AP4的这两种作用均被选择性拮抗剂MPPG减弱。单独应用时,MPPG(200微摩尔)对藜芦碱诱发的突触体45Ca2+摄取无可检测的作用。这些结果提示了突触前活性谷氨酸受体激动剂阻断电点燃诱导的慢性癫痫状态发展的机制,并表明它们的抗惊厥活性是由于阻断突触前Ca2+内流后抑制突触前谷氨酸和/或天冬氨酸释放所致。